Hims & Hers Health, Inc. (NYSE: HIMS) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $226.7 million versus the consensus estimate of $220.08 million.

GUIDANCE:

Hims & Hers Health, Inc. sees FY2023 revenue of $868-873 million, versus the consensus of $846.7 million. And Adjusted EBITDA guidance to a range of $43 million to $46 million.

For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.